Meta‐analysis: combination therapy with interferon‐α 2a/2b and ribavirin for patients with chronic hepatitis C previously non‐responsive to interferon

Miguel, Ramón San; Guillén, Francisco Camarelles; Cabasés, Juan M.; Buti, María

doi:10.1046/j.1365-2036.2002.01328.x

Cited by 18 publications

(18 citation statements)

References 58 publications

(104 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Each of these reviews included only RCTs in their primary analyses. Two reviews (Cheng 77 and San Miguel 80 ) used more stringent inclusion criteria with regard to doses of IFN and RBV, dose frequency and treatment duration. The other three reviews did not restrict inclusion based on these criteria.…”

Section: Results Of Previous Systematic Reviews Of Retreatmentmentioning

confidence: 99%

“…77,80 In the Cheng review 77 SVRs were determined after excluding studies containing the highest or lowest proportion of patients with the covariate. The overall SVR for trials that included more than 50% of patients with genotype 1 was decreased compared with the primary analysis.…”

Section: Results Of Previous Systematic Reviews Of Retreatmentmentioning

confidence: 99%

“…Minimal differences from the primary analysis were detected when sensitivity analyses were performed on trials varying in baseline levels of HCV RNA. The San Miguel review 80 considered trials with more than or less than 50% of patients with genotypes 1 and 4. The confidence intervals for these analyses overlapped, but a greater response was seen in trials with a lower proportion of patients with genotypes 1 and 4.…”

Section: Results Of Previous Systematic Reviews Of Retreatmentmentioning

confidence: 99%

See 2 more Smart Citations

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

Shepherd

Brodin²,

Cave³

et al. 2004

Health Technol Assess

191

133

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA Declared competing interests of authors:John Gabbay is Director of the NCCHTA, but is not directly involved in setting research agendas. He is also a member of the editorial board for Health Technology Assessment, although was not involved in the editorial process for this report. JG is a member of the consumer involvement steering group at the NCCHTA and also is a member of INVOLVE, which promotes public involvement in the NHS, public health and social care research. Published October 2004This report should be referenced as follows: NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness...

show abstract

Section: Results Of Previous Systematic Reviews Of Retreatmentmentioning

confidence: 99%

Section: Results Of Previous Systematic Reviews Of Retreatmentmentioning

confidence: 99%

Section: Results Of Previous Systematic Reviews Of Retreatmentmentioning

confidence: 99%

See 1 more Smart Citation

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

Shepherd

Brodin²,

Cave³

et al. 2004

Health Technol Assess

191

133

View full text Add to dashboard Cite

show abstract

“…However, these were tolerated. About 14% of patients withdrew from this study because of adverse events, which is a higher rate than that in treatment with interferon‐ α [8]. It was possibly related to the higher dose of interferon‐ β used in this study.…”

Section: Discussionmentioning

confidence: 99%

Racial differences in responses to interferon‐β‐1a in chronic hepatitis C unresponsive to interferon‐α: a better response in Chinese patients

Cheng

Marcellin

Bacon

et al. 2004

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Re-treatment with interferon-alpha alone for chronic hepatitis C nonresponders to interferon-alpha monotherapy is almost ineffective. This multicentre, randomized, parallel-group, dose-finding study evaluated the efficacy of interferon-beta-1a in the treatment of chronic hepatitis C patients unresponsive to interferon-alpha. A total of 267 patients were randomized to one of four groups: subcutaneous interferon-beta-1a 12 MIU (44 microg) or 24 MIU (88 microg) administered three times weekly or daily. Patients were treated for 48 weeks and then followed up for an additional 24 weeks. There was a trend towards a dose-response relationship regarding virological [loss of detectable serum hepatitis C virus (HCV) RNA] and biochemical response (normalization of serum alanine aminotransferase). Overall, 22 patients (8.3%) had a virological response at the end of treatment; nine patients (3.4%) had a sustained virological response (SVR). Strikingly, 21.7% (5/23) of Chinese patients achieved SVR. Univariate analysis revealed that race was the only variable related to SVR [odds ratio (OR) 16.6; 95% CI 4.1-67.3; P < 0.0001]. Multiple logistic regression analysis also confirmed that more Chinese patients achieved SVR than non-Chinese patients (OR 12.3; 95% CI 2.6-59.3; P = 0.0017). In addition, complete clearance of HCV-RNA occurred earlier in Chinese than in non-Chinese responders (median 2 vs 30 weeks; P = 0.020). Thirty-six patients were withdrawn from treatment because of adverse events. Most adverse events were mild or moderate in severity. In conclusion, interferon-beta-1a provided considerable clinical benefit in Chinese patients with chronic hepatitis C unresponsive to interferon-alpha. The evaluation of interferon-beta-1a in this setting is progressing.

show abstract

“…8 Re-treatment with similar regimen after the initial failure is not an optimal choice as the outcome is relatively poor. 9,10 Furthermore, the IFN-α based treatment is not without side effects. Patients often have to discontinue treatment due to intolerable side effects or reduce the treatment dosages to minimize such effects.…”

Section: Introductionmentioning

confidence: 99%

Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study

et al. 2009

View full text Add to dashboard Cite

Background/Aims: Interferon beta (IFN-β) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-β (IFN-β-1a) plus oral ribavirin versus interferon alpha (IFN-α) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). Methods: Twenty treatment-naïve patients were randomized into two equal-sized treatment groups. Both IFN-β-1a (44μg) and IFN-α (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. Results: After 24 weeks of treatment, six (60%) and four patients (40%) in the IFN-β-1a group and IFN-α groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40%). However, the baseline viral load was significantly higher (p=0.034) in the IFN-β-1a group than in the IFN-α group, and there were more HCV genotype 1 patients in the IFN-β-1a group (eight versus seven). The IFN-β-1a group was associated with similar adverse events in terms of frequency and severity. Conclusions: The SVR rate and safety profile were similar for the combination of IFN-β-1a and ribavirin and that of IFN-α and ribavirin.

show abstract

Meta‐analysis: combination therapy with interferon‐α 2a/2b and ribavirin for patients with chronic hepatitis C previously non‐responsive to interferon

Cited by 18 publications

References 58 publications

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

Racial differences in responses to interferon‐β‐1a in chronic hepatitis C unresponsive to interferon‐α: a better response in Chinese patients

Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study

Contact Info

Product

Resources

About